Envestnet Asset Management Inc Dbv Technologies S.A. Transaction History

Envestnet Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	SELL	$1.42 - $2.23 $20,084 - $31,541	-14,144 Reduced 38.6%	22,494 $42,000
Q1 2023 May 11, 2023	SELL	$1.28 - $1.73 $22,859 - $30,896	-17,859 Reduced 32.77%	36,638 $61,000
Q4 2022 Feb 07, 2023	BUY	$1.16 - $1.8 $19,104 - $29,644	16,469 Added 43.31%	54,497 $83,000
Q3 2022 Nov 10, 2022	BUY	$1.77 - $2.76 $67,309 - $104,957	38,028 New	38,028 $67,000
Q1 2022 May 04, 2022	SELL	$1.22 - $1.77 $32,528 - $47,193	-26,663 Closed	0 $0

Q4 2021 Feb 04, 2022	BUY	$1.39 - $5.58 $37,061 - $148,779	26,663 New	26,663 $43,000
Q4 2020 Feb 02, 2021	SELL	$1.38 - $3.01 $28,447 - $62,048	-20,614 Closed	0 $0
Q3 2020 Oct 09, 2020	BUY	$1.58 - $4.77 $1,862 - $5,623	1,179 Added 6.07%	20,614 $36,000
Q2 2020 Jul 08, 2020	BUY	$3.74 - $6.28 $72,686 - $122,051	19,435 New	19,435 $85,000

37.7M

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $175M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.